Рифампицин

Quick links

Choose a section

Quick links to important sections

Advertisements

Рифампицин

Selected form

Advertisements
Advertisements

Treatment option: Infection, Meningitis, Tuberculosis

Advertisements

Overview of Рифампицин

What is Rifampicin?

Property Description
Active Ingredient Rifampicin (Rifampin)
Form Capsule, Powder for Injection Solution
Pharmacological Class Rifamycin Antibiotic, Antitubercular Agent
Common Use Treatment of Severe Bacterial Infections
Origin Semisynthetic Derivative

What Type of Medicine is Rifampicin: Pharmacological Class and Identification

Rifampicin (INN: Rifampicin) is a potent, broad-spectrum antibiotic that belongs to the Rifamycin class of antimicrobial agents, distinguished by its unique molecular structure. This medication is clinically recognized for its essential role in treating chronic infections, leading to its formal classification as a crucial antitubercular agent and a drug against leprosy. As a specialized therapeutic option, its inclusion in the World Health Organization's List of Essential Medicines signifies its established effectiveness and public health importance. Rifampicin is typically reserved for prescription use, highlighting its necessity in managing severe, drug-sensitive infections within a controlled medical environment.


Composition, Origin, and Dosage Forms

The active ingredient is the compound Rifampicin, a semisynthetic derivative of its parent Rifamycin B, which enhances its pharmacological characteristics for superior clinical effectiveness. Rifampicin is formulated as a single-ingredient monopreparation and is available for patient use in two key dosage forms: hard capsules for oral administration and a powder for injection solution that is reconstituted with a sterile aqueous solvent for intravenous administration. This dual availability is a differentiating factor, as it permits rapid initiation of therapy with the injection, followed by maintenance with the capsule, ensuring seamless systemic treatment.


General Purpose and Bactericidal Principle

The general purpose of Rifampicin is to effectively treat severe bacterial infections by exerting a bactericidal effect—meaning it actively kills the targeted microbes. This potent, destructive capability is why the drug serves as a cornerstone in the initial and maintenance treatment regimens for complex, chronic diseases such as tuberculosis and leprosy. Pharmacological studies confirm this drug's selective toxicity, ensuring that it achieves its purpose by interfering with the bacteria’s vital life processes without significantly disrupting those of the human host.

Advertisements

What side effects are possible with Рифампицин?

Possible Side Effects and Safety Information

The safety profile for Rifampicin is formally categorized by regulatory bodies to communicate the range, frequency, and severity of documented adverse reactions. These effects are classified across several System-Organ Classes (SOCs), which detail the physiological systems potentially affected.

Adverse Reaction Classifications

Category Examples Regulator Frequency
Systemic/General Fever, chills Very Common
Gastrointestinal/Nervous System Nausea, vomiting, headache, dizziness Common
Hematologic Thrombocytopenia (low platelet count), Leukopenia Common / Uncommon

Serious Adverse Reactions and Organ Systems

Adverse reactions that are explicitly documented as serious in official labeling, though often categorized as Not Known or Rare in frequency, include Drug-Induced Liver Injury (Hepatitis), which can be fatal, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other serious effects involve the renal system, including Acute Renal Failure, and the lungs, with reports of Interstitial Lung Disease.

Safety Considerations and Limitations

The official label states that Rifampicin causes the red-orange discoloration of body fluids, including urine, sweat, and tears; this effect is expected and may permanently stain soft contact lenses. Specific safety notes exist for patients with pre-existing hepatic impairment due to the increased risk of liver toxicity. Caution is also noted regarding intermittent use or resumption of therapy after interruption, which is associated with a greater risk of immunological and renal hypersensitivity reactions.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documents state that Rifampicin overdose results in distinct physiological changes and potentially life-threatening systemic effects. A key documented sign is the dose-dependent brownish-red or orange discoloration affecting the skin and all body fluids, including the urine, sweat, saliva, tears, and faeces. Other manifestations include nausea, vomiting, abdominal pain, headache, and increasing lethargy.

Severe outcomes documented in regulatory sources primarily involve the liver and cardiovascular system. Overdose can lead to severe hepatic disease and jaundice, potentially progressing to unconsciousness. Other life-threatening complications include seizures, hypotension, ventricular arrhythmias, and cardiac arrest.

Emergency Response and Management

Immediate medical attention is required for any suspected overdose event. Regulatory guidance explicitly mandates contacting emergency services (e.g., 911) immediately if the individual is collapsed, has had a seizure, has trouble breathing, or cannot be awakened.

Management focuses on intensive supportive measures and decontamination procedures, such as gastric lavage and the administration of activated charcoal. This approach is necessary because no specific antidote is known for Rifampicin. Furthermore, official notes confirm the risk of unconsciousness is increased in the presence of severe hepatic disease, and special considerations apply to paediatric patients, where facial oedema has been reported.

Advertisements

Therapeutic Uses of Рифампицин

What Рифампицин treats: Main Uses and Benefits

Rifampicin is an antibiotic used for managing bacterial infections and addressing infection control, focusing on providing a crucial therapeutic action to address severe, underlying conditions. Its use is defined across three key therapeutic domains.

The medication is commonly used across conditions presenting with systemic or localized discomfort, primarily for the treatment of Tuberculosis (TB) and Leprosy. It is also relevant for managing severe deep-seated bacterial infections, including those affecting bone (osteomyelitis) and prosthetic joints, and for short-term chemoprophylaxis to manage the asymptomatic carrier state of high-risk bacteria.

In these situations, the medication helps ease the overall symptom burden by addressing the underlying infection. For patients with chronic disease, it supports general well-being during symptomatic phases by helping with managing symptoms like persistent fever and fatigue. For acute scenarios like prosthetic joint infections, its role in managing infections that cluster on implants assists with maintaining functional stability.

“Rifampicin is often applied in contexts where additional symptomatic support is needed against certain infections.”

Quick Fact Support for
Contributes to functional stability when infection creates noticeable physiological strain on implants and bone tissue. Deep-seated bacterial infections

Regulatory References

  1. New Zealand Medsafe datasheet
Advertisements

Eligibility and Restrictions for Use

Official Regulatory Eligibility and Restrictions

The eligibility profile for Rifampicin is strictly governed by governmental regulatory documents, defining clear rules for who may use the medicine and who is prohibited from use.

Contraindicated Populations (Must Not Use) Conditional/Restricted Use (Use with Caution)
History of hypersensitivity to Rifampicin or any rifamycin class drug. Patients with impaired liver function or pre-existing liver disease.
Acute liver disease, severe hepatic impairment, or jaundice. Severe renal impairment or anuria, particularly when doses exceed 600 mg daily.
Concomitant use with specific drugs, including lurasidone or the combination of saquinavir/ritonavir. Patients with a history of diabetes mellitus.
Newborn and premature infants (as an age-dependent exclusion). Older adults, requiring careful consideration of concurrent hepatic or renal issues.

Age-Group Eligibility: The medicine's use is established in adults and most pediatric populations, with doses determined by weight. However, its use is contraindicated in newborn and premature infants. Older adults are generally eligible, but concurrent organ impairment must be evaluated as per label guidance.

Pregnancy and Lactation: While generally permitted for serious infections during pregnancy, official labeling includes a warning regarding the risk of haemorrhagic disorders in the newborn if used in the last few weeks. Regulatory sources provide conflicting guidance on breastfeeding, ranging from compatible to not recommended.

Connection to the overall eligibility profile: The regulatory documentation defines eligibility primarily by excluding populations with severe liver dysfunction or known hypersensitivity. Conditional use is imposed on groups with organ impairment (renal, hepatic) or other comorbidities to ensure use strictly aligns with official, label-based restrictions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rifampicin's official regulatory profile is defined by its activity as a strong, broad-spectrum enzyme and transporter inducer, primarily involving CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein (P-gp). This pharmacokinetic mechanism significantly reduces the plasma concentration of numerous co-administered drugs, often leading to loss of their therapeutic effect.

Formally Contraindicated Combinations

Co-administration is strictly prohibited with several classes of medicinal products, including certain HIV protease inhibitors and antivirals (e.g., Atazanavir, Ritonavir-boosted Saquinavir, Daclatasvir). This prohibition is due to the potential for substantial decreases in drug exposure, leading to treatment failure, or the documented risk of severe hepatocellular toxicity (as with Ritonavir-boosted Saquinavir).

Other contraindicated medicines include Praziquantel and Lurasidone, as their effective therapeutic levels are significantly compromised.

Exposure-Modifying and Timing Constraints

The drug diminishes the efficacy of many medicines, including Oral Contraceptives, Coumarin-type Anticoagulants (necessitating increased dosage), Corticosteroids, and Oral Hypoglycemics. Additionally, official labeling mandates strict timing separation rules for administration: p-Aminosalicylic Acid (PAS) must be given at least four hours apart to prevent reduced Rifampicin serum levels. Furthermore, the drug's oral absorption is reduced by approximately 30% when ingested with food.

Advertisements

Mechanism of Action

Selective Inhibition of Bacterial Transcription


The molecule exerts its mechanism by binding specifically to the beta-subunit (RpoB) of bacterial RNA Polymerase (RNAP). This binding physically obstructs the enzyme's channel, halting transcription and preventing the synthesis of essential microbial proteins, leading directly to the rapid bactericidal effect and cellular death in susceptible pathogens.


Transcriptional Activation of Host Metabolism

Rifampicin also acts as an agonist for the host's nuclear receptors, notably the Pregnane X Receptor (PXR), which triggers the gene expression of drug-metabolizing enzymes (such as CYP3A4) in the liver. This action functionally accelerates the body's metabolic processing and systemic clearance rate of other co-administered substances.


Mechanism Limitation: Overcoming Target Affinity

The primary constraint on the drug's mechanism is a molecular change in the target: specific point mutations in the bacterial rpoB gene cause a conformational shift in RNAP. This structural alteration prevents Rifampicin from maintaining sufficient binding affinity, overriding the inhibitory mechanism.

Advertisements

Dosage and Administration Information

How to use Rifampicin: Official Administration Guidelines

Rifampicin administration is defined by established protocols, specifying the route, frequency, and required combination with other anti-infective agents. The medication is available as capsules for oral use and as a powder for intravenous (IV) infusion for patients who are severely ill or unable to take oral forms.

Oral doses are typically administered once daily, recommended to be taken on an empty stomach (one hour before or two hours after a meal) with a full glass of water, as food may reduce absorption. For children or adults unable to swallow capsules, a pharmacist can prepare an extemporaneous oral suspension.

Official Dosing and Regimens

Indication Adult Dose (Single Daily Dose unless noted) Maximum Daily Dose (Adults/Children)
Tuberculosis 10 mg/kg/day (up to 600 mg) 600 mg
Meningococcal Carrier 600 mg twice daily for 2 days 1200 mg (for 2-day course)
Pediatric Dosing 10–20 mg/kg/day 600 mg

Procedural and Time Constraints

For IV use, the 600 mg powder must first be reconstituted with 10 mL of sterile water, then diluted further for infusion over a period of 30 minutes to 3 hours. Treatment for tuberculosis typically involves an initial phase and continuation phase, totaling a minimum duration of six months. For most indications, the drug must be used in combination with at least one other active agent. Dosage adjustment is generally not required for renal failure when the dose is 600 mg daily or less; however, caution and lower doses are advised for patients with hepatic impairment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rifampicin

This overview describes the research landscape for Rifampicin, focusing on the types of studies conducted and what their findings indicate, without offering personal advice or clinical guidance. The evidence is drawn from official regulatory and peer-reviewed scientific sources.

Evidence for Use in Tuberculosis (TB)

Research exploring Rifampicin's role in the management of active Tuberculosis is supported by an extensive history of large-scale Randomized Controlled Trials (RCTs) and numerous Systematic Reviews. These studies have mainly focused on combination regimens, as Rifampicin is typically included as a component alongside other medicines for this condition. The key outcomes monitored in these trials include the successful microbiological clearance of the bacteria and the long-term risk of disease relapse.

Studies reported measurements of bacteriological clearance in study populations. Findings describe patterns of low treatment failure and relapse observed in study populations when patients completed the full course of combination treatment regimens. What remains uncertain is the optimal approach for patients receiving higher Rifampicin doses intended to shorten the total duration of therapy, as existing evidence is still emerging and may be associated with increased variability in drug levels between patients.

Evidence for Deep-Seated Bacterial Infections

Rifampicin was evaluated in studies focused on severe, complex, and chronic infections, such as Prosthetic Joint Infections (PJI) caused by Staphylococcus bacteria. The research consists primarily of Observational Cohort Studies and a limited number of Small Randomized Controlled Trials (RCTs). Studies monitored endpoints such as the rate of infection recurrence and treatment failure over follow-up durations often extending to two years.

Observational data show patterns related to the inclusion of Rifampicin in combination with other antibiotics, and its use was observed in studies evaluating implant retention. However, the evidence base for PJI is limited due to a lack of multiple, large, modern RCTs. Additionally, results apply only to the specific populations studied, and data for infections caused by bacteria other than staphylococcus remain insufficient.

What is Still Uncertain About Rifampicin Research

Scientific and regulatory analyses consistently point to several areas where research is ongoing and certainty remains low. Official research and guidelines note that limited information is available on the efficacy and optimal use of Rifampicin in certain groups, such as children aged below 14 years and in pregnant and lactating women.

For non-TB infections like PJI, comparative evidence is lacking from large, high-quality RCTs, leaving some uncertainty about the benefits of adding Rifampicin compared to other antibiotic strategies. Overall, while the drug’s role in treating TB is well-defined, its use in other complex infections and in special populations remains an area for further research to provide clearer insight into outcomes.

Key Studies & References

  1. NIH National Library of Medicine: Information on Rifampicin use in special populations (e.g., HIV co-infection)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Рифампицин (FAQ)

Q: Why does Рифампицин turn urine and tears orange?

This color change is a known and expected effect. The active ingredient in Рифампицин and its natural breakdown products (metabolites) are inherently reddish-brown. When these are processed by the body and passed out, they cause the dramatic discoloration of body fluids, which is generally harmless.

Q: Can Рифампицин be used to treat infections other than tuberculosis?

Yes. While it is a cornerstone in tuberculosis management, official product information also indicates its use for treating asymptomatic carriers of Neisseria meningitidis to help eliminate the bacteria from the nasopharynx. It is also used as a component in combination with other medicines for certain severe bacterial infections.

Q: What are the most common side effects of Рифампицин reported by patients?

Official documents classify several side effects based on how frequently they were reported in studies. The most common or very common reactions include flu-like symptoms such as fever and chills, as well as gastrointestinal and nervous system effects like nausea, vomiting, headache, and dizziness.

Q: Can Рифампицин affect birth control pills?

Yes, regulatory information clearly states that Рифампицин is a strong inducer of drug-metabolizing enzymes. This action can accelerate the breakdown of hormonal contraceptives in the body, which may significantly reduce their effectiveness.

Q: Is there a link between Рифампицин and liver problems?

Official warnings describe a link between Рифампицин use and the potential for liver injury (hepatotoxicity), which can be severe. Due to this concern, the drug is formally contraindicated in people with severe, active liver disease. Regulatory guidance advises regular monitoring of liver function.

Q: What color changes in body fluids are caused by Рифампицин?

Рифампицин causes a harmless red-orange discoloration in several body fluids, including urine, sweat, tears, saliva, and feces. It is also noted in official documents that the drug can permanently stain soft contact lenses.

Q: How does the official literature describe the use of Рифампицин during breastfeeding?

Official guidance on the use of Рифампицин while breastfeeding is variable. Some sources suggest it is compatible, while others advise caution or state it is not recommended, since the drug is known to pass into breast milk.

Q: Is it normal to feel nauseous when starting Рифампицин?

Nausea and vomiting are listed in regulatory documents as common adverse reactions associated with the use of the drug. These effects are frequently reported by patients, particularly when first beginning therapy.

Q: How long does it typically take for Рифампицин to start working?

The mechanism of action for Рифампицин is described as resulting in a rapid bactericidal effect on susceptible bacteria. The time it takes for the medicine to reach its peak concentration in the bloodstream is typically within a few hours of administration.

Q: Is Рифампицин safe for children?

Official drug documents establish its use in most pediatric populations, with the dose determined by body weight. However, it is explicitly contraindicated (must not be used) in newborn and premature infants.

Q: Can older adults use Рифампицин?

Older adults are generally eligible for use. However, official documents note that concurrent organ impairment, particularly hepatic (liver) or renal (kidney) issues, must be considered during evaluation.

Q: What happens if a dose of Рифампицин is missed?

Official patient information emphasizes that skipping doses or stopping early can prevent the infection from being fully treated. More critically, this can potentially result in the targeted bacteria becoming resistant and thus harder to treat in the future.

Q: Can I take Рифампицин if I have kidney disease?

Dosage adjustment is typically not required for general renal failure when the daily dose is 600 mg or less. However, caution and lower doses are noted in official documents for patients with severe renal impairment.

Q: Are there restrictions on activities like driving while taking Рифампицин?

Regulatory documents list side effects like dizziness and headache as common adverse reactions. Patients should be aware of these potential effects and consider how they might impact the ability to safely perform activities like driving.

Q: Has Рифампицин been studied for use in preventing infections?

Yes, besides its role in treating active disease, the drug is officially indicated for eliminating Neisseria meningitidis bacteria from the nasopharynx in asymptomatic carriers. This is a form of prophylactic (preventative) use.

Q: What happens when Рифампицин is stopped suddenly?

Official safety notes caution that interrupting the therapy and then resuming it is associated with a greater risk of severe immunological and renal (kidney) hypersensitivity reactions.

Q: Does Рифампицин interfere with general anesthesia for surgery?

Due to its strong enzyme-inducing properties, regulatory documents note that the concomitant use of Рифампицин and certain anesthetic agents, such as halothane, should be avoided due to the potential for adverse drug interactions.

Q: Are there any known issues with taking Рифампицин with blood pressure medications?

Yes, because Рифампицин accelerates drug-metabolizing enzymes, it can reduce the concentration of many medications in the blood. This includes some used for blood pressure, heart disease, and irregular heartbeat, potentially lowering their effectiveness.

Q: Is Рифампицин ever used as a single-drug therapy?

While it is typically used in combination with other agents for conditions like tuberculosis, official documents indicate it is used as a single agent for the treatment of asymptomatic carriers of Neisseria meningitidis.

Q: Are there any common interactions with antacids or iron supplements?

Official product information notes that taking aluminum-containing antacids too close to Рифампицин can reduce the amount of the drug absorbed by the body. This may affect the overall effectiveness of the treatment.

Q: Is there a risk of developing a new infection while taking Рифампицин?

Official warnings describe a risk of developing a severe intestinal infection called Clostridium difficile-associated diarrhea (CDAD). This risk is associated with using many antibiotics, including Рифампицин, and may occur during or after treatment.

Q: What kind of monitoring is typically required while on Рифампицин?

Regulatory guidance advises regular monitoring of organ function during treatment. This typically includes blood tests to check liver function (transaminases and bilirubin levels) and regular monitoring of blood counts.

Q: How does Рифампицин affect alcohol consumption?

Official warnings indicate that drinking alcohol regularly while taking the medicine may increase the risk of liver problems due to the combined effect on the liver. Official documents state that alcohol consumption should be strictly limited or avoided during treatment.

Q: Is Рифампицин safe to take during pregnancy?

Use during pregnancy is permitted for serious infections, but official documents contain a warning regarding the risk of haemorrhagic disorders (bleeding problems) in the newborn if the drug is used in the last few weeks of pregnancy.

Q: Does taking Рифампицин require a special diet?

No specific diet is required. However, official documents state that taking the drug with food can reduce the amount of medicine absorbed by the body. For this reason, administration on an empty stomach is generally specified in official instructions.

Advertisements

How should Рифампицин be stored and disposed of?

How to Store and Dispose of Rifampicin

The storage of Rifampicin capsules must adhere to Controlled Room Temperature, defined as the range between 20 C and 25 C (68 F and 77 F). The medication must be protected from excessive heat and moisture.

Storage Protection and Handling

Requirement Condition
Container Must be dispensed in a tight, light-resistant container and kept tightly closed during storage.
Temperature Limit Avoid excessive heat; the prepared injection solution must not be frozen.
Stability The constituted solution for injection must be used within 24 hours.
Child Safety Store the medication out of the reach of children.

Disposal Instructions

Expired or unused Rifampicin should not be flushed down the toilet or poured into a drain. Disposal must follow all applicable federal, state, and local requirements, with a medicine take-back program being the preferred method for discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Рифампицин found in:

A-Z Index: